摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Tert-butyl 4-[(2-hydroxy-2-quinolin-3-ylethyl)amino]piperidine-1-carboxylate | 935262-84-3

中文名称
——
中文别名
——
英文名称
Tert-butyl 4-[(2-hydroxy-2-quinolin-3-ylethyl)amino]piperidine-1-carboxylate
英文别名
——
Tert-butyl 4-[(2-hydroxy-2-quinolin-3-ylethyl)amino]piperidine-1-carboxylate化学式
CAS
935262-84-3
化学式
C21H29N3O3
mdl
——
分子量
371.48
InChiKey
CYWSALJIBFECPF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    27
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    74.7
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Tert-butyl 4-[(2-hydroxy-2-quinolin-3-ylethyl)amino]piperidine-1-carboxylate4-二甲氨基吡啶三乙酰氧基硼氢化钠三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 生成 3-[1-(1H-indol-2-ylmethyl)piperidin-4-yl]-5-quinolin-3-yl-1,3-oxazolidin-2-one
    参考文献:
    名称:
    Oxazolidinones as novel human CCR8 antagonists
    摘要:
    High-throughput screening of the corporate compound collection led to the discovery of a novel series of N-substituted-5-aryl-oxazolidinones as potent human CCR8 antagonists. The synthesis, structure-activity relationships, and optimization of the series that led to the identification of SB-649701 (1a), are described. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.12.076
  • 作为产物:
    描述:
    参考文献:
    名称:
    Oxazolidinones as novel human CCR8 antagonists
    摘要:
    High-throughput screening of the corporate compound collection led to the discovery of a novel series of N-substituted-5-aryl-oxazolidinones as potent human CCR8 antagonists. The synthesis, structure-activity relationships, and optimization of the series that led to the identification of SB-649701 (1a), are described. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.12.076
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED 3-AMINO-THIENO[2,3-B] PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AS IKK INHIBITORS<br/>[FR] COMPOSES AMIDE D'ACIDE 3-AMINO-THIENO[2,3-B] PYRIDINE-2-CARBOXYLIQUE SUBSTITUE SERVANT D'INHIBITEURS D'IKK
    申请人:BOEHRINGER INGELHEIM PHARMA
    公开号:WO2005056562A1
    公开(公告)日:2005-06-23
    Disclosed are compounds of formula (I): wherein the variables R1, R2, R3 and Z are described herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
    披露了公式(I)的化合物:其中变量R1、R2、R3和Z如本文所述,它们作为IκB激酶(IKK)复合物的激酶活性的抑制剂是有用的。因此,这些化合物在治疗IKK介导的疾病,包括自身免疫性疾病、炎症性疾病和癌症方面是有用的。还披露了包含这些化合物的药物组合物以及制备这些化合物的方法。
  • SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
    申请人:Chen Zhidong
    公开号:US20080312185A1
    公开(公告)日:2008-12-18
    Disclosed are methods of treating cancer by administration of compounds according to formula (I): wherein the variables R 1 , R 2 , R 3 and Z are described herein.
    公开了一种使用公式(I)的化合物治疗癌症的方法,其中变量R1、R2、R3和Z的描述如下。
  • Oxazolidinones as novel human CCR8 antagonists
    作者:Jian Jin、Yonghui Wang、Feng Wang、Jeffery K. Kerns、Victoria M. Vinader、Ashley P. Hancock、Matthew J. Lindon、Graeme I. Stevenson、Dwight M. Morrow、Parvathi Rao、Cuc Nguyen、Victoria J. Barrett、Chris Browning、Guido Hartmann、David P. Andrew、Henry M. Sarau、James J. Foley、Anthony J. Jurewicz、James A. Fornwald、Andy J. Harker、Michael L. Moore、Ralph A. Rivero、Kristen E. Belmonte、Helen E. Connor
    DOI:10.1016/j.bmcl.2006.12.076
    日期:2007.3
    High-throughput screening of the corporate compound collection led to the discovery of a novel series of N-substituted-5-aryl-oxazolidinones as potent human CCR8 antagonists. The synthesis, structure-activity relationships, and optimization of the series that led to the identification of SB-649701 (1a), are described. (c) 2006 Elsevier Ltd. All rights reserved.
查看更多